Cargando…
Management and Treatment Outcomes of High-Risk Corneal Transplantations
Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572799/ https://www.ncbi.nlm.nih.gov/pubmed/36233379 http://dx.doi.org/10.3390/jcm11195511 |
_version_ | 1784810706860769280 |
---|---|
author | Urbańska, Karolina Woźniak, Marcin Więsyk, Piotr Konarska, Natalia Bartos, Weronika Biszewski, Mateusz Bielak, Michał Chorągiewicz, Tomasz Rejdak, Robert |
author_facet | Urbańska, Karolina Woźniak, Marcin Więsyk, Piotr Konarska, Natalia Bartos, Weronika Biszewski, Mateusz Bielak, Michał Chorągiewicz, Tomasz Rejdak, Robert |
author_sort | Urbańska, Karolina |
collection | PubMed |
description | Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more susceptible to rejection. These are so-called high-risk corneal transplantations. In our study, we selected 52 patients with a higher risk of graft rejection. A total of 78 procedures were performed. The main indications for the first keratoplasty were infections (59.6%) and traumas (21.2%). Visual acuity (VA) significantly improved from 2.05 logMAR on the day of keratoplasty to 1.66 logMAR in the latest examination (p = 0.003). An analysis of the graft survival showed a 1-year survival of 54% and a 5-year survival of 19.8% of grafts. The mean observation time without complications after the first, second, and third surgery was 23, 13, and 14 months, respectively. The best results were noted among patients with infectious indications for keratoplasty (p = 0.001). Among them, those with bacterial infection had the best visual outcomes (p = 0.047). |
format | Online Article Text |
id | pubmed-9572799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95727992022-10-17 Management and Treatment Outcomes of High-Risk Corneal Transplantations Urbańska, Karolina Woźniak, Marcin Więsyk, Piotr Konarska, Natalia Bartos, Weronika Biszewski, Mateusz Bielak, Michał Chorągiewicz, Tomasz Rejdak, Robert J Clin Med Article Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more susceptible to rejection. These are so-called high-risk corneal transplantations. In our study, we selected 52 patients with a higher risk of graft rejection. A total of 78 procedures were performed. The main indications for the first keratoplasty were infections (59.6%) and traumas (21.2%). Visual acuity (VA) significantly improved from 2.05 logMAR on the day of keratoplasty to 1.66 logMAR in the latest examination (p = 0.003). An analysis of the graft survival showed a 1-year survival of 54% and a 5-year survival of 19.8% of grafts. The mean observation time without complications after the first, second, and third surgery was 23, 13, and 14 months, respectively. The best results were noted among patients with infectious indications for keratoplasty (p = 0.001). Among them, those with bacterial infection had the best visual outcomes (p = 0.047). MDPI 2022-09-20 /pmc/articles/PMC9572799/ /pubmed/36233379 http://dx.doi.org/10.3390/jcm11195511 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Urbańska, Karolina Woźniak, Marcin Więsyk, Piotr Konarska, Natalia Bartos, Weronika Biszewski, Mateusz Bielak, Michał Chorągiewicz, Tomasz Rejdak, Robert Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title | Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title_full | Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title_fullStr | Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title_full_unstemmed | Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title_short | Management and Treatment Outcomes of High-Risk Corneal Transplantations |
title_sort | management and treatment outcomes of high-risk corneal transplantations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572799/ https://www.ncbi.nlm.nih.gov/pubmed/36233379 http://dx.doi.org/10.3390/jcm11195511 |
work_keys_str_mv | AT urbanskakarolina managementandtreatmentoutcomesofhighriskcornealtransplantations AT wozniakmarcin managementandtreatmentoutcomesofhighriskcornealtransplantations AT wiesykpiotr managementandtreatmentoutcomesofhighriskcornealtransplantations AT konarskanatalia managementandtreatmentoutcomesofhighriskcornealtransplantations AT bartosweronika managementandtreatmentoutcomesofhighriskcornealtransplantations AT biszewskimateusz managementandtreatmentoutcomesofhighriskcornealtransplantations AT bielakmichał managementandtreatmentoutcomesofhighriskcornealtransplantations AT choragiewicztomasz managementandtreatmentoutcomesofhighriskcornealtransplantations AT rejdakrobert managementandtreatmentoutcomesofhighriskcornealtransplantations |